Alembic Pharmaceuticals Ltd. (APLLTD) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 807696, "name": "Alembic Pharma", "stock_name": "Alembic Pharma", "full_name": "Alembic Pharmaceuticals Ltd.", "name_url": "stocks-analysis/alembic-pharma", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "796.95", "chg": -12.8, "chgp": "-1.58%", "dir": -1, "prev_price": "809.75", "mcapval": "15,308.00 Cr", "mcap": "Small Cap", "scripcode": 533573, "symbol": "APLLTD", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE901L01018", "curr_date": "Feb 06", "curr_time": "", "bse_nse_vol": "1.19 lacs", "exc_status": "Active", "traded_date": "Feb 06, 2026", "traded_date_str": "2026 02 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alembic-pharma-807696-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Alembic Pharmaceuticals Gains 2.23%: Margin Pressures and Flat Trends Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-gains-223-margin-pressures-and-flat-trends-shape-the-week-3826327", "imagepath": "", "date": "2026-02-07 15:04:25", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock opens at Rs.781.80 amid Sensex decline</p>\n <p><strong>3 Feb:</strong> Price rises 1.16% to Rs.790.90 as Sensex surges 2.63%</p>\n <p><strong>5 Feb:</strong> Q3 FY26 results reveal profit decline and margin pressure</p>\n <p><strong>6 Feb:</strong> Flat quarterly performance reported; stock closes at Rs.799.05 (-1.32%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.781.80</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"..." }, { "title": "Alembic Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-reports-flat-quarterly-performance-amid-margin-pressures-3823489", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AlembicPharmace_fintrenddot_3823489.png", "date": "2026-02-06 08:00:18", "description": "Alembic Pharmaceuticals Ltd. has reported a flat financial performance for the quarter ended December 2025, marking a notable shift from its previously positive growth trajectory. Despite a 21.0% increase in quarterly profit after tax (PAT), other key financial indicators such as earnings per share (EPS) and inventory turnover have shown signs of strain, prompting a downgrade in the company’s Mojo Grade from Hold to Sell as of 25 Nov 2025." }, { "title": "Alembic Pharmaceuticals Q3 FY26: Profit Decline Amid Margin Pressure Raises Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/alembic-pharmaceuticals-q3-fy26-profit-decline-amid-margin-pressure-raises-concerns-3822814", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AlembicPharmace_quaterlyResult_3822814.png", "date": "2026-02-05 17:47:34", "description": "Alembic Pharmaceuticals Ltd. reported a concerning 28.01% quarter-on-quarter decline in consolidated net profit for Q3 FY26, with earnings falling to ₹132.97 crores from ₹184.71 crores in Q2 FY26. The Vadodara-based pharmaceutical manufacturer, with a market capitalisation of ₹15,922 crores, witnessed its stock trading at ₹801.70 following the results announcement, reflecting investor disappointment with the sequential deterioration in profitability despite modest year-on-year growth of 10.84% in net sales." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3812504", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AlembicPharmace_mojoScore_3812504.png", "date": "2026-01-31 10:10:33", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3795861", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AlembicPharmace_mojoScore_3795861.png", "date": "2026-01-20 10:10:43", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Why is Alembic Pharmaceuticals Ltd. falling/rising?", "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-alembic-pharmaceuticals-ltd-fallingrising-3787705", "imagepath": "", "date": "2026-01-10 01:28:01", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>The stock has underperformed both its sector and benchmark indices consistently. Over the last week, Alembic Pharmaceuticals has fallen by 4.64%, significantly lagging behind the Sensex’s 2.55% decline. This underperformance extends to the one-month period, where the stock dropped 9.68% compared to the Sensex’s modest 1.29% fall. Year-to-date, the stock has declined by 5.60%, again underperforming the broader market’s 1.93% decrease. Such persistent weakness is compounded by the fact that the stock has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical outlook.</p>\n<p>Investor participation has increased, with delivery volumes on 08 Jan risi..." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3786720", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AlembicPharmace_mojoScore_3786720.png", "date": "2026-01-09 10:10:44", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3772248", "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharmace_mojoScore_3772248.png", "date": "2025-12-28 10:10:03", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook." }, { "title": "Alembic Pharma Sees Revision in Market Assessment Amid Mixed Financial Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharma-downgraded-to-sell-by-marketsmojo-amid-weak-financial-trends-3761135", "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharma_mojoScore_3761135.png", "date": "2025-12-17 10:10:32", "description": "Alembic Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued stock performance and sector dynamics." } ], "total": 5261, "sid": "807696", "stock_news_url": "https://www.marketsmojo.com/news/alembic-pharmaceuticals-807696" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "06-Feb-2026", "details": "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Carbidopa Levodopa and Entacapone Tablets", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "06-Feb-2026", "details": "Newspaper Publication of Unaudited Financials Results for the Quarter and Nine Months Ended 31st December 2025", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate", "datetime": "05-Feb-2026", "details": "Please find attached the intimation of appointment of Mr. Raj Kumar Baheti (DIN:00332079) as Non-Executive Non Independent Director of the Company.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Alembic Pharmaceuticals Ltd. has declared <strong>550%</strong> dividend, ex-date: 29 Jul 25", "dt": "2025-07-29", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: Stock opens at Rs.781.80 amid Sensex decline

3 Feb: Price rises 1.16% to Rs.790.90 as Sensex surges 2.63%

5 Feb: Q3 FY26 results reveal profit decline and margin pressure

6 Feb: Flat quarterly performance reported; stock closes at Rs.799.05 (-1.32%)

Week Open

Rs.781.80

Week Close

Read full news article

Alembic Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures

2026-02-06 08:00:18

Alembic Pharmaceuticals Ltd. has reported a flat financial performance for the quarter ended December 2025, marking a notable shift from its previously positive growth trajectory. Despite a 21.0% increase in quarterly profit after tax (PAT), other key financial indicators such as earnings per share (EPS) and inventory turnover have shown signs of strain, prompting a downgrade in the company’s Mojo Grade from Hold to Sell as of 25 Nov 2025.

Read full news article

Alembic Pharmaceuticals Q3 FY26: Profit Decline Amid Margin Pressure Raises Concerns

2026-02-05 17:47:34

Alembic Pharmaceuticals Ltd. reported a concerning 28.01% quarter-on-quarter decline in consolidated net profit for Q3 FY26, with earnings falling to ₹132.97 crores from ₹184.71 crores in Q2 FY26. The Vadodara-based pharmaceutical manufacturer, with a market capitalisation of ₹15,922 crores, witnessed its stock trading at ₹801.70 following the results announcement, reflecting investor disappointment with the sequential deterioration in profitability despite modest year-on-year growth of 10.84% in net sales.

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2026-01-31 10:10:33

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2026-01-20 10:10:43

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Why is Alembic Pharmaceuticals Ltd. falling/rising?

2026-01-10 01:28:01

Recent Price Movement and Market Performance

The stock has underperformed both its sector and benchmark indices consistently. Over the last week, Alembic Pharmaceuticals has fallen by 4.64%, significantly lagging behind the Sensex’s 2.55% decline. This underperformance extends to the one-month period, where the stock dropped 9.68% compared to the Sensex’s modest 1.29% fall. Year-to-date, the stock has declined by 5.60%, again underperforming the broader market’s 1.93% decrease. Such persistent weakness is compounded by the fact that the stock has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical outlook.

Investor participation has increased, with delivery volumes on 08 Jan risi...

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2026-01-09 10:10:44

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2025-12-28 10:10:03

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Alembic Pharma Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-17 10:10:32

Alembic Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued stock performance and sector dynamics.

Read full news article

View All News